U.S., April 25 -- ClinicalTrials.gov registry received information related to the study (NCT06941870) titled 'Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy' on April 16.
Brief Summary: The objective of the study is to assess the improvement of synovial hypertrophy during the 12 months of efanesoctocog alfa prophylaxis once per week (QW) in joints with existing evidence of synovial hypertrophy in participants with hemophilia A.
The study duration for each participant is approximately 12 months.
Study Start Date: May 30
Study Type: INTERVENTIONAL
Condition:
Factor VIII Deficiency
Intervention:
DRUG: Efanesoctocog alfa
Pharmaceutical form:Lyophilized powder in a sterile vial that requires recon...